GENE ONLINE|News &
Opinion
Blog

Pfizer/BioNTech
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
Pfizer and BioNTech Kickstart Trial For Combination Vaccine for Influenza and COVID-19
2022-11-04
Pfizer/BioNTech’s Omicron Booster Snags Another FDA Emergency Use Authorization
2022-10-12
The COVID-19 Pandemic: Is Omicron the Last Variant?
2022-09-16
FDA Approves Both Moderna’s and Pfizer/BioNTech’s Omicron Bivalent Vaccines in One Day
2022-08-31
Moderna’s Lawsuit Against Pfizer/BioNTech: What Does This Mean for Their Vaccine’s future?
2022-08-26
Pfizer-BioNTech COVID-19 Vaccine Proven Effective in Young Children
2022-08-23
Pfizer and BioNTech’s New Bivalent Omicron Vaccine Lined Up for Authorization from the FDA
2022-08-22
CureVac Files mRNA Patent Lawsuit Against BioNTech in Germany
2022-07-06
FDA Panel Suggests Redesigning Vaccines to Target Omicron Variants, Pfizer & Sanofi Share Booster Updates
2022-06-29
New Study Suggests Vaccines Protect against Long COVID
2022-01-28
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
COVID-19: Pfizer/BioNTech Say Their Vaccine is Safe and Protective in 5- to 11-Year-Olds
2021-09-20
Mu COVID Variant Could Potentially Escape Immunity But Delta is Still “Most Concerning”, WHO Says
2021-09-08
Pfizer/BioNTech’s COVID-19 Vaccine Notches Full Approval from USFDA
2021-08-23
1 2
LATEST
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top